| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Molecular Diagnostic Techniques | 8 | 2020 | 4239 | 1.65 | Why? |
| Alphavirus Infections | 2 | 2017 | 68 | 1.30 | Why? |
| Nucleic Acid Amplification Techniques | 6 | 2020 | 3388 | 1.16 | Why? |
| RNA, Viral | 21 | 2021 | 32276 | 1.00 | Why? |
| DNA Viruses | 2 | 2019 | 184 | 0.85 | Why? |
| High-Throughput Nucleotide Sequencing | 6 | 2021 | 3633 | 0.82 | Why? |
| Yellow fever virus | 2 | 2018 | 205 | 0.80 | Why? |
| Transplantation | 1 | 2019 | 72 | 0.78 | Why? |
| Viremia | 4 | 2020 | 1020 | 0.76 | Why? |
| DNA Virus Infections | 1 | 2019 | 88 | 0.76 | Why? |
| Yellow Fever | 2 | 2018 | 231 | 0.73 | Why? |
| Reagent Kits, Diagnostic | 5 | 2021 | 2149 | 0.72 | Why? |
| Clinical Laboratory Techniques | 8 | 2020 | 23402 | 0.72 | Why? |
| Fluorescent Antibody Technique | 1 | 2021 | 835 | 0.71 | Why? |
| O'nyong-nyong Virus | 1 | 2017 | 9 | 0.71 | Why? |
| Proviruses | 1 | 2017 | 82 | 0.69 | Why? |
| Viral Envelope Proteins | 2 | 2020 | 3539 | 0.69 | Why? |
| Seizures, Febrile | 1 | 2017 | 59 | 0.66 | Why? |
| Alphavirus | 1 | 2017 | 90 | 0.66 | Why? |
| Point-of-Care Testing | 2 | 2020 | 2782 | 0.65 | Why? |
| Real-Time Polymerase Chain Reaction | 10 | 2021 | 11367 | 0.65 | Why? |
| Anopheles | 1 | 2017 | 89 | 0.64 | Why? |
| Poliovirus | 1 | 2017 | 109 | 0.63 | Why? |
| Nucleocapsid | 1 | 2021 | 734 | 0.63 | Why? |
| Metagenomics | 2 | 2019 | 823 | 0.62 | Why? |
| Poliovirus Vaccine, Oral | 1 | 2017 | 95 | 0.61 | Why? |
| Tumor Virus Infections | 1 | 2017 | 127 | 0.60 | Why? |
| RNA Stability | 1 | 2017 | 285 | 0.59 | Why? |
| BK Virus | 1 | 2017 | 135 | 0.59 | Why? |
| Polyomavirus Infections | 1 | 2017 | 156 | 0.58 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2021 | 533 | 0.57 | Why? |
| Urine | 1 | 2017 | 469 | 0.57 | Why? |
| Dengue Virus | 4 | 2019 | 910 | 0.55 | Why? |
| Papillomaviridae | 1 | 2019 | 404 | 0.55 | Why? |
| Plasma | 3 | 2021 | 1809 | 0.52 | Why? |
| Nasopharynx | 8 | 2021 | 10224 | 0.52 | Why? |
| Papillomavirus Infections | 2 | 2019 | 861 | 0.51 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 11 | 2021 | 13720 | 0.46 | Why? |
| Mutation | 9 | 2021 | 12376 | 0.45 | Why? |
| Uterine Cervical Neoplasms | 2 | 2019 | 842 | 0.44 | Why? |
| Opportunistic Infections | 1 | 2017 | 602 | 0.42 | Why? |
| Zika Virus | 4 | 2017 | 1924 | 0.42 | Why? |
| Zika Virus Infection | 4 | 2017 | 1920 | 0.39 | Why? |
| Dengue | 4 | 2019 | 1565 | 0.39 | Why? |
| Point-of-Care Systems | 2 | 2020 | 2955 | 0.37 | Why? |
| Ebolavirus | 1 | 2015 | 834 | 0.37 | Why? |
| HIV-1 | 3 | 2018 | 3365 | 0.36 | Why? |
| Viral Load | 5 | 2021 | 15850 | 0.34 | Why? |
| Mass Screening | 5 | 2020 | 8005 | 0.34 | Why? |
| Betacoronavirus | 15 | 2020 | 204454 | 0.34 | Why? |
| Microbiota | 1 | 2017 | 1240 | 0.33 | Why? |
| Antibodies, Viral | 12 | 2021 | 51949 | 0.33 | Why? |
| Immunoglobulin G | 7 | 2021 | 21571 | 0.32 | Why? |
| Blood Donors | 1 | 2020 | 2956 | 0.32 | Why? |
| California | 4 | 2020 | 2047 | 0.32 | Why? |
| Severe Dengue | 2 | 2019 | 135 | 0.31 | Why? |
| Humans | 73 | 2021 | 930598 | 0.29 | Why? |
| Receptors, IgG | 2 | 2020 | 578 | 0.29 | Why? |
| Sensitivity and Specificity | 10 | 2021 | 22971 | 0.28 | Why? |
| Viruses | 2 | 2019 | 2238 | 0.28 | Why? |
| Antibody Formation | 2 | 2020 | 4038 | 0.28 | Why? |
| Coronavirus Infections | 16 | 2021 | 253789 | 0.28 | Why? |
| Pneumonia, Viral | 15 | 2020 | 243684 | 0.28 | Why? |
| DNA, Viral | 4 | 2019 | 2521 | 0.27 | Why? |
| Hemorrhagic Fever, Ebola | 1 | 2015 | 1475 | 0.27 | Why? |
| Diagnostic Tests, Routine | 3 | 2021 | 2643 | 0.27 | Why? |
| Multiplex Polymerase Chain Reaction | 3 | 2020 | 1439 | 0.26 | Why? |
| False Negative Reactions | 2 | 2020 | 1785 | 0.26 | Why? |
| Drug Resistance, Viral | 3 | 2018 | 1083 | 0.25 | Why? |
| Reproducibility of Results | 5 | 2020 | 11304 | 0.24 | Why? |
| Zimbabwe | 2 | 2019 | 198 | 0.23 | Why? |
| Transplant Recipients | 2 | 2018 | 4982 | 0.23 | Why? |
| Immunologic Tests | 2 | 2021 | 445 | 0.23 | Why? |
| Isotachophoresis | 1 | 2020 | 8 | 0.22 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.22 | Why? |
| Enzyme-Linked Immunosorbent Assay | 4 | 2021 | 7868 | 0.22 | Why? |
| Immunocompromised Host | 1 | 2017 | 5150 | 0.21 | Why? |
| Specimen Handling | 6 | 2021 | 6190 | 0.21 | Why? |
| Adult | 30 | 2021 | 244371 | 0.20 | Why? |
| Disease Transmission, Infectious | 2 | 2021 | 9044 | 0.20 | Why? |
| Sequence Analysis, DNA | 3 | 2017 | 2830 | 0.20 | Why? |
| DNA, Fungal | 1 | 2019 | 95 | 0.20 | Why? |
| Virus Replication | 1 | 2021 | 14331 | 0.19 | Why? |
| Interferon-gamma Release Tests | 1 | 2021 | 253 | 0.19 | Why? |
| Genotype | 3 | 2021 | 4697 | 0.19 | Why? |
| Vaginal Smears | 1 | 2019 | 89 | 0.19 | Why? |
| Prostatitis | 1 | 2018 | 18 | 0.19 | Why? |
| DNA-Directed RNA Polymerases | 1 | 2020 | 239 | 0.19 | Why? |
| Microfluidics | 1 | 2020 | 171 | 0.19 | Why? |
| Semiconductors | 1 | 2018 | 25 | 0.19 | Why? |
| Stochastic Processes | 1 | 2020 | 369 | 0.19 | Why? |
| Nephritis | 1 | 2018 | 39 | 0.19 | Why? |
| Lymphoma, Large-Cell, Anaplastic | 1 | 2018 | 24 | 0.18 | Why? |
| Lymphoma, T-Cell | 1 | 2018 | 70 | 0.18 | Why? |
| Child, Preschool | 9 | 2021 | 36283 | 0.18 | Why? |
| Eye Infections, Parasitic | 1 | 2017 | 9 | 0.18 | Why? |
| Nicaragua | 1 | 2017 | 71 | 0.17 | Why? |
| Africa, Eastern | 1 | 2017 | 90 | 0.17 | Why? |
| Automation, Laboratory | 1 | 2020 | 536 | 0.17 | Why? |
| DNA, Protozoan | 1 | 2017 | 77 | 0.17 | Why? |
| Retrospective Studies | 11 | 2021 | 105322 | 0.17 | Why? |
| Female | 30 | 2021 | 380317 | 0.17 | Why? |
| Forkhead Transcription Factors | 1 | 2018 | 231 | 0.16 | Why? |
| Nasopharyngeal Neoplasms | 1 | 2017 | 64 | 0.16 | Why? |
| Virus Inactivation | 2 | 2017 | 1139 | 0.16 | Why? |
| Time Factors | 5 | 2020 | 31397 | 0.16 | Why? |
| Roseolovirus Infections | 1 | 2017 | 131 | 0.16 | Why? |
| Cell-Free Nucleic Acids | 1 | 2019 | 271 | 0.16 | Why? |
| Middle Aged | 23 | 2021 | 270681 | 0.16 | Why? |
| Polyethylene Glycols | 1 | 2021 | 574 | 0.16 | Why? |
| Cytomegalovirus | 2 | 2018 | 600 | 0.15 | Why? |
| Calibration | 1 | 2017 | 307 | 0.15 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.15 | Why? |
| Herpesvirus 6, Human | 1 | 2017 | 162 | 0.15 | Why? |
| Cervix Uteri | 1 | 2017 | 146 | 0.15 | Why? |
| Male | 28 | 2021 | 367725 | 0.15 | Why? |
| HIV Infections | 3 | 2018 | 11620 | 0.15 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2017 | 309 | 0.15 | Why? |
| CD4 Lymphocyte Count | 2 | 2017 | 1517 | 0.15 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 526 | 0.15 | Why? |
| Insect Vectors | 1 | 2017 | 227 | 0.15 | Why? |
| DNA, Bacterial | 1 | 2019 | 835 | 0.15 | Why? |
| Interleukins | 1 | 2021 | 762 | 0.15 | Why? |
| Spike Glycoprotein, Coronavirus | 4 | 2021 | 37182 | 0.14 | Why? |
| Microcephaly | 1 | 2017 | 181 | 0.14 | Why? |
| Transplantation Conditioning | 1 | 2017 | 323 | 0.14 | Why? |
| 5' Untranslated Regions | 1 | 2017 | 375 | 0.14 | Why? |
| Cytomegalovirus Infections | 2 | 2018 | 667 | 0.14 | Why? |
| Blood Cell Count | 1 | 2020 | 1101 | 0.14 | Why? |
| RNA Viruses | 2 | 2020 | 824 | 0.14 | Why? |
| Immunogenicity, Vaccine | 2 | 2021 | 4624 | 0.14 | Why? |
| Infant | 6 | 2020 | 30274 | 0.14 | Why? |
| Chikungunya virus | 1 | 2017 | 339 | 0.13 | Why? |
| Uveitis | 1 | 2017 | 233 | 0.13 | Why? |
| Aedes | 1 | 2017 | 380 | 0.13 | Why? |
| Feasibility Studies | 2 | 2021 | 3467 | 0.13 | Why? |
| Area Under Curve | 1 | 2021 | 2564 | 0.13 | Why? |
| Influenza A Virus, H3N2 Subtype | 1 | 2018 | 572 | 0.13 | Why? |
| Herpesvirus 4, Human | 1 | 2017 | 387 | 0.13 | Why? |
| Case-Control Studies | 4 | 2021 | 17671 | 0.13 | Why? |
| Health Personnel | 2 | 2020 | 29646 | 0.13 | Why? |
| Hematopoietic Stem Cell Transplantation | 2 | 2017 | 2426 | 0.13 | Why? |
| Child | 9 | 2020 | 70012 | 0.13 | Why? |
| Vaccination | 1 | 2019 | 19050 | 0.13 | Why? |
| Base Sequence | 2 | 2021 | 3581 | 0.13 | Why? |
| Health Planning | 1 | 2020 | 607 | 0.12 | Why? |
| Antibody-Dependent Enhancement | 1 | 2017 | 413 | 0.12 | Why? |
| Pericardial Effusion | 1 | 2017 | 312 | 0.12 | Why? |
| Infant, Newborn, Diseases | 1 | 2017 | 394 | 0.12 | Why? |
| Aspartate Aminotransferases | 1 | 2019 | 1394 | 0.12 | Why? |
| Hospital Bed Capacity | 1 | 2020 | 1300 | 0.12 | Why? |
| Immunoglobulin A | 3 | 2020 | 3567 | 0.12 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 952 | 0.12 | Why? |
| Pregnancy Complications, Infectious | 1 | 2017 | 11559 | 0.11 | Why? |
| CRISPR-Cas Systems | 1 | 2020 | 1397 | 0.11 | Why? |
| Polymerase Chain Reaction | 4 | 2021 | 6740 | 0.11 | Why? |
| Immune Evasion | 1 | 2021 | 2081 | 0.10 | Why? |
| Nanotechnology | 1 | 2017 | 821 | 0.10 | Why? |
| Early Detection of Cancer | 2 | 2019 | 1956 | 0.10 | Why? |
| Genes, Viral | 1 | 2015 | 1428 | 0.10 | Why? |
| Eye Infections, Viral | 1 | 2017 | 517 | 0.10 | Why? |
| Aged | 16 | 2021 | 215776 | 0.10 | Why? |
| Viral Nonstructural Proteins | 2 | 2017 | 4810 | 0.10 | Why? |
| Mycobacterium tuberculosis | 1 | 2018 | 1164 | 0.09 | Why? |
| ROC Curve | 1 | 2021 | 6024 | 0.09 | Why? |
| Nanoparticles | 1 | 2021 | 2040 | 0.09 | Why? |
| Poverty | 2 | 2019 | 2302 | 0.09 | Why? |
| Mexico | 1 | 2017 | 2787 | 0.09 | Why? |
| Epidemiological Monitoring | 1 | 2021 | 3493 | 0.09 | Why? |
| Nucleocapsid Proteins | 1 | 2020 | 3120 | 0.09 | Why? |
| Serologic Tests | 2 | 2020 | 4359 | 0.09 | Why? |
| Prevalence | 2 | 2020 | 25773 | 0.09 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.08 | Why? |
| Temperature | 1 | 2017 | 2305 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.08 | Why? |
| Virus Shedding | 2 | 2021 | 5834 | 0.08 | Why? |
| Pandemics | 16 | 2020 | 389249 | 0.08 | Why? |
| Rural Population | 1 | 2019 | 2408 | 0.08 | Why? |
| Young Adult | 11 | 2021 | 93724 | 0.08 | Why? |
| Azithromycin | 1 | 2021 | 3943 | 0.08 | Why? |
| Infant, Newborn | 4 | 2020 | 23105 | 0.07 | Why? |
| Animals | 5 | 2018 | 78931 | 0.07 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.07 | Why? |
| B-Lymphocytes | 1 | 2020 | 4418 | 0.07 | Why? |
| Adolescent | 7 | 2020 | 86841 | 0.07 | Why? |
| Ecuador | 2 | 2017 | 514 | 0.07 | Why? |
| Treatment Failure | 2 | 2021 | 2106 | 0.07 | Why? |
| Premature Birth | 1 | 2017 | 2151 | 0.07 | Why? |
| Influenza, Human | 2 | 2021 | 10779 | 0.07 | Why? |
| Protein Binding | 1 | 2021 | 11430 | 0.07 | Why? |
| Genome, Viral | 3 | 2021 | 13157 | 0.07 | Why? |
| Aged, 80 and over | 8 | 2020 | 88759 | 0.07 | Why? |
| Computational Biology | 1 | 2019 | 4514 | 0.07 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.07 | Why? |
| Fever | 2 | 2019 | 7795 | 0.07 | Why? |
| Emergency Medical Services | 1 | 2020 | 3557 | 0.06 | Why? |
| Feces | 1 | 2017 | 4235 | 0.06 | Why? |
| Cross Reactions | 3 | 2021 | 4374 | 0.06 | Why? |
| Genetic Variation | 1 | 2017 | 3919 | 0.06 | Why? |
| Asthma | 1 | 2021 | 4383 | 0.06 | Why? |
| Kidney Failure, Chronic | 1 | 2018 | 3222 | 0.06 | Why? |
| Influenza Vaccines | 1 | 2018 | 2941 | 0.06 | Why? |
| Sequence Analysis, RNA | 2 | 2021 | 2290 | 0.06 | Why? |
| DNA Fingerprinting | 1 | 2021 | 41 | 0.06 | Why? |
| Immunogenetics | 1 | 2020 | 124 | 0.05 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2017 | 5164 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2019 | 5002 | 0.05 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.05 | Why? |
| Cohort Studies | 3 | 2019 | 36005 | 0.05 | Why? |
| Anti-Bacterial Agents | 1 | 2021 | 10083 | 0.05 | Why? |
| Miniaturization | 1 | 2018 | 29 | 0.05 | Why? |
| Respiratory Tract Infections | 1 | 2020 | 6817 | 0.05 | Why? |
| Lymphoma, T-Cell, Peripheral | 1 | 2018 | 12 | 0.05 | Why? |
| Injections, Subcutaneous | 1 | 2021 | 647 | 0.05 | Why? |
| Vero Cells | 1 | 2015 | 14117 | 0.05 | Why? |
| Sri Lanka | 1 | 2019 | 241 | 0.05 | Why? |
| Eggs | 1 | 2018 | 43 | 0.05 | Why? |
| Human T-lymphotropic virus 1 | 1 | 2018 | 52 | 0.05 | Why? |
| Sequence Analysis | 1 | 2020 | 496 | 0.05 | Why? |
| Conserved Sequence | 1 | 2021 | 751 | 0.05 | Why? |
| Mycoplasma pneumoniae | 1 | 2020 | 233 | 0.05 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.04 | Why? |
| Kidney Transplantation | 1 | 2018 | 5397 | 0.04 | Why? |
| HIV Integrase | 1 | 2018 | 67 | 0.04 | Why? |
| HIV Reverse Transcriptase | 1 | 2018 | 104 | 0.04 | Why? |
| Colony Count, Microbial | 1 | 2018 | 177 | 0.04 | Why? |
| Toxoplasmosis, Ocular | 1 | 2017 | 5 | 0.04 | Why? |
| Incidence | 2 | 2017 | 25622 | 0.04 | Why? |
| Pregnancy | 2 | 2017 | 23879 | 0.04 | Why? |
| Outpatients | 2 | 2021 | 3417 | 0.04 | Why? |
| Herpes Zoster Ophthalmicus | 1 | 2017 | 17 | 0.04 | Why? |
| DNA Probes | 1 | 2018 | 178 | 0.04 | Why? |
| Chicago | 1 | 2020 | 653 | 0.04 | Why? |
| Toxoplasma | 1 | 2017 | 61 | 0.04 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.04 | Why? |
| Single-Blind Method | 1 | 2021 | 1283 | 0.04 | Why? |
| Seasons | 2 | 2021 | 4071 | 0.04 | Why? |
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 243 | 0.04 | Why? |
| Simplexvirus | 1 | 2017 | 124 | 0.04 | Why? |
| United States | 2 | 2020 | 46150 | 0.04 | Why? |
| Glycosylation | 1 | 2020 | 1255 | 0.04 | Why? |
| Vitreous Body | 1 | 2017 | 161 | 0.04 | Why? |
| Fungi | 1 | 2019 | 471 | 0.04 | Why? |
| Prostate | 1 | 2018 | 283 | 0.04 | Why? |
| Patient Outcome Assessment | 1 | 2020 | 707 | 0.04 | Why? |
| Antibiotic Prophylaxis | 1 | 2018 | 399 | 0.04 | Why? |
| Blood Specimen Collection | 1 | 2019 | 387 | 0.04 | Why? |
| Body Fluids | 1 | 2019 | 451 | 0.04 | Why? |
| Adaptation, Physiological | 1 | 2018 | 359 | 0.04 | Why? |
| Host-Pathogen Interactions | 1 | 2015 | 11041 | 0.04 | Why? |
| Herpesvirus 3, Human | 1 | 2017 | 228 | 0.04 | Why? |
| Allografts | 1 | 2018 | 761 | 0.04 | Why? |
| Likelihood Functions | 1 | 2017 | 719 | 0.04 | Why? |
| Diagnostic Self Evaluation | 1 | 2019 | 394 | 0.04 | Why? |
| Washington | 1 | 2020 | 1722 | 0.04 | Why? |
| Transplantation, Homologous | 1 | 2017 | 757 | 0.04 | Why? |
| Genome, Bacterial | 1 | 2018 | 446 | 0.03 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.03 | Why? |
| Administration, Oral | 1 | 2021 | 2340 | 0.03 | Why? |
| Herpes Simplex | 1 | 2017 | 272 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2019 | 1444 | 0.03 | Why? |
| Chikungunya Fever | 1 | 2017 | 345 | 0.03 | Why? |
| Nasal Mucosa | 1 | 2020 | 1218 | 0.03 | Why? |
| Ferrets | 1 | 2018 | 1201 | 0.03 | Why? |
| T-Lymphocytes, Regulatory | 1 | 2018 | 698 | 0.03 | Why? |
| Self Care | 1 | 2020 | 918 | 0.03 | Why? |
| Antibody Affinity | 1 | 2017 | 1078 | 0.03 | Why? |
| Platelet Count | 1 | 2017 | 1381 | 0.03 | Why? |
| Antiviral Agents | 2 | 2021 | 41703 | 0.03 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.03 | Why? |
| Antigens, Viral | 2 | 2018 | 6298 | 0.03 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2020 | 2483 | 0.03 | Why? |
| Whole Genome Sequencing | 1 | 2021 | 3239 | 0.03 | Why? |
| Phenotype | 1 | 2021 | 4037 | 0.03 | Why? |
| Bayes Theorem | 1 | 2019 | 3237 | 0.02 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.02 | Why? |
| Disease Outbreaks | 1 | 2017 | 27595 | 0.02 | Why? |
| Phylogeny | 2 | 2018 | 13341 | 0.02 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.02 | Why? |
| Bacteria | 1 | 2019 | 1897 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Biomarkers, Tumor | 1 | 2017 | 1314 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2019 | 4758 | 0.02 | Why? |
| Evolution, Molecular | 1 | 2021 | 3691 | 0.02 | Why? |
| Symptom Assessment | 1 | 2021 | 4967 | 0.02 | Why? |
| Congresses as Topic | 1 | 2017 | 1347 | 0.02 | Why? |
| Electronic Health Records | 1 | 2020 | 3492 | 0.02 | Why? |
| HEK293 Cells | 1 | 2020 | 8394 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.02 | Why? |
| Forecasting | 1 | 2020 | 4492 | 0.02 | Why? |
| Blood Platelets | 1 | 2017 | 1704 | 0.02 | Why? |
| Anti-HIV Agents | 1 | 2018 | 2209 | 0.02 | Why? |
| Biomarkers | 2 | 2019 | 23361 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Kidney | 1 | 2018 | 3648 | 0.02 | Why? |
| T-Lymphocytes | 1 | 2021 | 6670 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Thrombocytopenia | 1 | 2017 | 2093 | 0.02 | Why? |
| Models, Statistical | 1 | 2020 | 5312 | 0.02 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.02 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Risk Factors | 2 | 2017 | 71621 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Risk Assessment | 1 | 2019 | 25439 | 0.01 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.01 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.01 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.01 | Why? |
| Coronavirus | 1 | 2021 | 18339 | 0.01 | Why? |